Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2019

15.11.2018 | Clinical trial

YouTube English videos as a source of information on breast self-examination

verfasst von: Ebru Esen, Mehmet Aslan, Bilgehan Çağdaş Sonbahar, Ramazan Saygın Kerimoğlu

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

To examine the content, quality and reliability of YouTube videos related to breast self-examination.

Design

A search of YouTube was made on 21.06.2018 using the keyword of “breast self-examination”. The videos were categorised by two doctors as useful information or misleading information. To evaluate the quality of the videos, a 5-point global quality scale was used (GQS: 1 = poor quality, 5 = excellent quality), for reliability a 5-point DISCERN scale was used, and for content an 8-point scale (higher points indicated greater reliability and better content).

Results

Of the 200 videos initially included in the study, 33 (37.9%) were classified as useful and 54 (62%) as misleading information. The reliability, content and quality scores of the videos in the useful information group were higher. The length (in seconds) of the videos in the useful information group (median 301, IQR 231–512) was longer than that of those in the misleading information group (median 163, IQR 94.8–231) (p = 0.003). The majority (70.6%) of the videos in the misleading information group had been uploaded by an individual user. The number of views per day of the videos in the misleading information group (median 58.6, IQR 18.5–298) was greater than that of the videos in the useful information group (median 49.7, IQR 16.3–268) (p = 0.276). The number of total views was higher for the misleading information group (median 83807 vs. 80237) but not at a level of statistical significance (p = 0.153). There were more videos explaining breast self-examination directed at women only, and there were determined to be few videos including men only or both genders.

Conclusion

Although there are many videos in English related to breast self-examination on YouTube, a great many of these contain misleading information. Therefore, for public information, there is a need for videos with full and accurate information to be made by universities, healthcare organisations and doctors not benefitting from the outcomes, to be uploaded to YouTube, which is a currently important source of information for the general population.
Literatur
1.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108CrossRefPubMed
2.
Zurück zum Zitat Elmore JG, Armstrong K, Lehman CD, Fletcher SW (2005) Screening for breast cancer. J Am Med Assoc 293(10):1245–1256CrossRef Elmore JG, Armstrong K, Lehman CD, Fletcher SW (2005) Screening for breast cancer. J Am Med Assoc 293(10):1245–1256CrossRef
3.
Zurück zum Zitat Bevers TB, Helvie M et al. NCCN guidelines: breast cancer screening and diagnosis, Version 3.2018 Bevers TB, Helvie M et al. NCCN guidelines: breast cancer screening and diagnosis, Version 3.2018
4.
Zurück zum Zitat Baxter N (2001) Canadian task force on preventive health care. Preventive health care, 2001 update: should women be routinely taught breast self-examination to screen for breast cancer? Can Med Assoc J 164(13):1837–1846 Baxter N (2001) Canadian task force on preventive health care. Preventive health care, 2001 update: should women be routinely taught breast self-examination to screen for breast cancer? Can Med Assoc J 164(13):1837–1846
5.
Zurück zum Zitat Thomas DB, Gao DL, Ray RM et al (2002) Randomized trial of breast self examination in Shanghai: final results. J Natl Cancer Inst Cancer 94(19):1445–1457CrossRef Thomas DB, Gao DL, Ray RM et al (2002) Randomized trial of breast self examination in Shanghai: final results. J Natl Cancer Inst Cancer 94(19):1445–1457CrossRef
6.
Zurück zum Zitat Kosters JP, Gotzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Rev 2003(2):CD003373 Kosters JP, Gotzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Rev 2003(2):CD003373
8.
Zurück zum Zitat Bevers TB (2009) Breast awareness: a shift in the paradigm of breast self-examination. J Natl Compr Canc Netw 7(10):1042–1043CrossRefPubMed Bevers TB (2009) Breast awareness: a shift in the paradigm of breast self-examination. J Natl Compr Canc Netw 7(10):1042–1043CrossRefPubMed
9.
Zurück zum Zitat Vahabi M (2003) Breast cancer screening methods: a review of the evidence. Health Care Women Int 24(9):773–793CrossRefPubMed Vahabi M (2003) Breast cancer screening methods: a review of the evidence. Health Care Women Int 24(9):773–793CrossRefPubMed
19.
Zurück zum Zitat Charnock D, Shepperd S, Needham G, Gann R (1999) DISCERN: an instrument for judging the quality of written consumer health information on treatment choices. J Epidemiol Community Health 53(2):105–111CrossRefPubMedPubMedCentral Charnock D, Shepperd S, Needham G, Gann R (1999) DISCERN: an instrument for judging the quality of written consumer health information on treatment choices. J Epidemiol Community Health 53(2):105–111CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Bernard A, Langille M, Hughes S, Rose C, Leddin D, Veldhuyzen van Zanten S (2007) A systematic review of patient inflammatory bowel disease information resources on the World Wide Web. Am J Gastroenterol 102(9):2070–2077CrossRefPubMed Bernard A, Langille M, Hughes S, Rose C, Leddin D, Veldhuyzen van Zanten S (2007) A systematic review of patient inflammatory bowel disease information resources on the World Wide Web. Am J Gastroenterol 102(9):2070–2077CrossRefPubMed
22.
Zurück zum Zitat Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004) Breast carcinoma in men: a population-based study. Cancer 101(1):51–57CrossRefPubMed Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004) Breast carcinoma in men: a population-based study. Cancer 101(1):51–57CrossRefPubMed
23.
Metadaten
Titel
YouTube English videos as a source of information on breast self-examination
verfasst von
Ebru Esen
Mehmet Aslan
Bilgehan Çağdaş Sonbahar
Ramazan Saygın Kerimoğlu
Publikationsdatum
15.11.2018
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-5044-z

Weitere Artikel der Ausgabe 3/2019

Breast Cancer Research and Treatment 3/2019 Zur Ausgabe

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.